NasdaqGS:BIIBBiotechs
Biogen (BIIB) Valuation Check As New Lecanemab Persistence Data Support Alzheimer’s Franchise Potential
Biogen (BIIB) is back in focus after Eisai and the company shared new real-world data at AD/PD 2026, showing that many patients remain on Alzheimer’s drug lecanemab beyond the initial 18-month treatment period.
See our latest analysis for Biogen.
Despite the positive lecanemab and pipeline headlines in recent weeks, Biogen’s share price has eased, with a 1-month share price return of a 5.5% decline and a 7-day return of a 1% decline, while the 1-year total shareholder return of 28.15%...